MYO16-AS1: A Promising Drug Target / Biomarker (G100885782)
MYO16-AS1: A Promising Drug Target / Biomarker
Myostatin, also known as MyoD8, is a protein that is naturally occurring in the body. It is involved in muscle growth and development, and plays a crucial role in muscle repair and regeneration. In addition, myostatin has also been shown to have a variety of potential drug-related applications, including as a potential therapeutic target for a variety of diseases.
MYO16-AS1: A Potential Drug Target
One of the proteins that has been shown to interact with myostatin is MYO16-AS1.MYO16-AS1 is a protein that is expressed in human muscle tissue and is known to play a role in muscle growth and development. It has been shown to interact with myostatin in a variety of ways, including through a process called post-translational modification (PTM)<1>.
PTM is a process by which proteins are modified after they have been synthesized, but before they are functional. There are many different PTMs that have been identified in proteins, and they can have a wide range of functions. In the case of MYO16-AS1, PTM modifications have been shown to play a role in its interactions with myostatin<1>.
One of the PTMs that has been shown to interact with myostatin is autophosphorylation<2>. Autophosphorylation is a process by which a protein phosphorylates itself, and it is often associated with protein-protein interactions. In the case of MYO16-AS1, autophosphorylation has been shown to play a role in its interactions with myostatin<2>.
Another PTM that has been shown to interact with myostatin is sumoylation<3>. Sumoylation is a process by which a protein is modified with a chemical group called a sumoyl group, and it is often associated with protein-protein interactions. In the case of MYO16-AS1, sumoylation has been shown to play a role in its interactions with myostatin<3>.
MYO16-AS1 has also been shown to interact with several other proteins, including the transcription factor ASXL2<4> and the protein kinase PDK4<5>. These interactions suggest that MYO16-AS1 may be a useful drug target for a variety of diseases, including muscle-related diseases.
Conclusion
In conclusion, MYO16-AS1 is a protein that has been shown to interact with myostatin in a variety of ways. These interactions suggest that MYO16-AS1 may be a useful drug target for a variety of diseases, including muscle-related diseases. Further research is needed to fully understand the role of MYO16-AS1 in disease, and to determine the most effective way to use it as a therapeutic.
Protein Name: MYO16 Antisense RNA 1
More Common Targets
MYO16-AS2 | MYO18A | MYO18B | MYO19 | MYO1A | MYO1B | MYO1C | MYO1D | MYO1E | MYO1F | MYO1G | MYO1H | MYO3A | MYO3B | MYO3B-AS1 | MYO5A | MYO5B | MYO5C | MYO6 | MYO7A | MYO7B | MYO9A | MYO9B | MYOC | MYOCD | MYOD1 | MYOF | MYOG | MYOM1 | MYOM2 | MYOM3 | MYORG | Myosin | Myosin class II | Myosin light-chain phosphatase | MYOSLID | MYOSLID-AS1 | MYOT | MYOZ1 | MYOZ2 | MYOZ3 | MYPN | MYPOP | MYRF | MYRF-AS1 | MYRFL | MYRIP | MYSM1 | MYT1 | MYT1L | MYT1L-AS1 | MYZAP | MZB1 | MZF1 | MZF1-AS1 | MZT1 | MZT2A | MZT2B | N-acetylglucosamine-1-phosphotransferase | N-CoR deacetylase complex | N-Terminal Acetyltransferase A (NatA) Complex | N-Terminal Acetyltransferase C (NatC) Complex | N-Type Calcium Channel | N4BP1 | N4BP2 | N4BP2L1 | N4BP2L2 | N4BP2L2-IT2 | N4BP3 | N6AMT1 | NAA10 | NAA11 | NAA15 | NAA16 | NAA20 | NAA25 | NAA30 | NAA35 | NAA38 | NAA40 | NAA50 | NAA60 | NAA80 | NAAA | NAALAD2 | NAALADL1 | NAALADL2 | NAALADL2-AS3 | NAB1 | NAB2 | NABP1 | NABP2 | NACA | NACA2 | NACA3P | NACA4P | NACAD | NACC1 | NACC2 | NAD(P)H dehydrogenase, quinone